AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29876978 — intervention group
Group type: COMPARATOR
Intervention: Observational audit
Number of subjects: 58
Study 26546845 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sedation
Number of subjects: 0
Study 26546845 — intervention group
Group type: COMPARATOR
Intervention: Deep sedation/general anesthesia
Number of subjects: 0
Study 24169821 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% human albumin (HA)
Number of subjects: 240
Study 24169821 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES)
Number of subjects: 240
Study 24169821 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 240
Study 22290132 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (34 observers)
Number of subjects: 64
Study 22290132 — intervention group
Group type: COMPARATOR
Intervention: Nontraining group (30 observers)
Number of subjects: 64
Study 20557390 — intervention group
Group type: EXPERIMENTAL
Intervention: Information audiotape given the day prior to hospital discharge, encouraged to listen multiple times.
Number of subjects: 120
Study 20557390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no audiotape intervention).
Number of subjects: 120
Study 18958169 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing a hated face
Number of subjects: 17
Study 15825529 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride ophthalmic solution, one instillation four times daily for 21 days
Number of subjects: 49
Study 15825529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drops)
Number of subjects: 49
Study 12586622 — intervention group
Group type: EXPERIMENTAL
Intervention: IEmRNA
Number of subjects: 80
Study 12586622 — intervention group
Group type: COMPARATOR
Intervention: Antigenemia
Number of subjects: 80
Study 10506606 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoCyt 50 mg once every 2 weeks
Number of subjects: 28
Study 10506606 — intervention group
Group type: COMPARATOR
Intervention: Free ara-C 50 mg twice a week for 1 month
Number of subjects: 28
Study 10506606 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoCyt
Number of subjects: 28
Study 10506606 — intervention group
Group type: COMPARATOR
Intervention: Free ara-C
Number of subjects: 28
Study 8894655 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 50 IU/kg b.w. s.c. b.i.d.
Number of subjects: 20
Study 8894655 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 75 IU/kg b.w. s.c. b.i.d.
Number of subjects: 20
Study 8894655 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 100 IU/kg b.w. s.c. b.i.d.
Number of subjects: 20
Study 8894655 — intervention group
Group type: COMPARATOR
Intervention: Control group (Heparin)
Number of subjects: 20
Study 7963170 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated interview style
Number of subjects: 82
Study 7963170 — intervention group
Group type: COMPARATOR
Intervention: Nonintegrated interview style
Number of subjects: 82
Study 2821643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg
Number of subjects: 6
Study 2821643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2 mg
Number of subjects: 6
Study 2821643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2 mg and 4 mg
Number of subjects: 6
Study 2821643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31833020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating Matters intervention
Number of subjects: 3301
Study 31833020 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care TDV prevention program
Number of subjects: 3301
Study 30070742 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric stretch with cooling (6°C)
Number of subjects: 9
Study 30070742 — intervention group
Group type: COMPARATOR
Intervention: Gastric stretch (37°C)
Number of subjects: 9
Study 30070742 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil capsules (menthol)
Number of subjects: 9
Study 26806710 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional paper letters (TPL)
Number of subjects: 721
Study 26806710 — intervention group
Group type: EXPERIMENTAL
Intervention: Short text messages (STM)
Number of subjects: 721
Study 26806710 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 721
Study 27196485 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg administered before surgery)
Number of subjects: 83
Study 23583433 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg eluxadoline
Number of subjects: 807
Study 23583433 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg eluxadoline
Number of subjects: 807
Study 23583433 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg eluxadoline
Number of subjects: 807
Study 23583433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 807
Study 21916043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultragrivac vaccine with 10 day interval
Number of subjects: 100
Study 21916043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultragrivac vaccine with 21 day interval
Number of subjects: 100
Study 21916043 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 10 day interval
Number of subjects: 100
Study 21916043 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 21 day interval
Number of subjects: 100
Study 19212269 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body magnetic resonance imaging (WB-MRI) combined with whole-body magnetic resonance angiography (WB-MRA)
Number of subjects: 65
Study 16905951 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate red wine consumption (one glass daily for 3 weeks)
Number of subjects: 0
Study 14963287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral microdialysis (MD)
Number of subjects: 13
Study 11298665 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg on day 7 with propranolol 80 mg twice daily for 7 days
Number of subjects: 12
Study 11298665 — intervention group
Group type: COMPARATOR
Intervention: Almotriptan 12.5 mg on day 7 without propranolol
Number of subjects: 12
Study 10674661 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cell/recombinant B subunit cholera vaccine
Number of subjects: 216
Study 10674661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 8697924 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (ASA, 50mg/day) for more than two weeks
Number of subjects: 11
Study 2752277 — intervention group
Group type: EXPERIMENTAL
Intervention: DS (word recognition and decoding skills)
Number of subjects: 178
Study 2752277 — intervention group
Group type: EXPERIMENTAL
Intervention: OWLS (oral and written language)
Number of subjects: 178
Study 2752277 — intervention group
Group type: COMPARATOR
Intervention: CSS (classroom survival skills, alternative treatment control)
Number of subjects: 178
Study 786671 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 786671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 0
Study 786671 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen (up to 400 mg)
Number of subjects: 0
Study 30987867 — intervention group
Group type: EXPERIMENTAL
Intervention: SVM method
Number of subjects: 46
Study 30987867 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear formulation method
Number of subjects: 46
Study 28445790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led group treatment for insomnia based on cognitive behavioral therapy techniques; 2 days of training for nurses.
Number of subjects: 165
Study 28445790 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 165
Study 25677254 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 228
Study 25677254 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (Ph)
Number of subjects: 228
Study 25677254 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (Comb)
Number of subjects: 228
Study 25677254 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 228
Study 23720354 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-agent chemotherapy including high dose methotrexate, Ara-C, and intrathecal treatment
Number of subjects: 463
Study 23720354 — intervention group
Group type: COMPARATOR
Intervention: CNS positive group
Number of subjects: 463
Study 20644123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-negative SLNs
Number of subjects: 240
Study 20644123 — intervention group
Group type: COMPARATOR
Intervention: Tumor-positive SLNs
Number of subjects: 240
Study 20644123 — intervention group
Group type: COMPARATOR
Intervention: Factors predictive of tumor-positive SLNs
Number of subjects: 240
Study 20644123 — intervention group
Group type: COMPARATOR
Intervention: Factors associated with worse overall survival
Number of subjects: 240
Study 18385263 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (10 IU i.v.)
Number of subjects: 40
Study 18385263 — intervention group
Group type: COMPARATOR
Intervention: Methylergometrine (0.2 mg i.v.)
Number of subjects: 40
Study 18385263 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (10 IU i.v.) in normal controls (n=10)
Number of subjects: 40
Study 16863695 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic (HALS) approach
Number of subjects: 36
Study 12799128 — intervention group
Group type: EXPERIMENTAL
Intervention: New Moves program (intervention)
Number of subjects: 201
Study 12799128 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 11110856 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal perception of the onset of lactation
Number of subjects: 60
Study 11110856 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed maternal perception
Number of subjects: 60
Study 11110856 — intervention group
Group type: EXPERIMENTAL
Intervention: Low milk transfer
Number of subjects: 60
Study 2407754 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (N = 25)
Number of subjects: 36
Study 2407754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 11)
Number of subjects: 36
Study 38822 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 33
Study 38822 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 33
Study 38822 — intervention group
Group type: EXPERIMENTAL
Intervention: oxprenolol
Number of subjects: 33
Study 38822 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol
Number of subjects: 33
Study 31691153 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate and polyester mesh
Number of subjects: 54
Study 31691153 — intervention group
Group type: COMPARATOR
Intervention: Control (staples)
Number of subjects: 54
Study 30982995 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (G1): 18-35 years old
Number of subjects: 44
Study 30982995 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (G2): 40-60 years old
Number of subjects: 44
Study 29079101 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine Lot A
Number of subjects: 651
Study 29079101 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine Lot B
Number of subjects: 651
Study 29079101 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine Lot C
Number of subjects: 651
Study 29079101 — intervention group
Group type: COMPARATOR
Intervention: Solicited symptoms, unsolicited AEs, and SAEs
Number of subjects: 651
Study 29079101 — intervention group
Group type: COMPARATOR
Intervention: Serious AEs (SAEs)
Number of subjects: 651
Study 29079101 — intervention group
Group type: COMPARATOR
Intervention: Potential immune-mediated diseases (pIMDs)
Number of subjects: 651
Study 25681466 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature management at 33°C
Number of subjects: 652
Study 25681466 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature management at 36°C
Number of subjects: 652
Study 25681466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac arrest survivors
Number of subjects: 652
Study 25681466 — intervention group
Group type: COMPARATOR
Intervention: Control group of matched patients with ST-segment-elevation myocardial infarction
Number of subjects: 652
Study 23839254 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic membrane (CM) with periodontal pocket therapy
Number of subjects: 10
Study 23839254 — intervention group
Group type: COMPARATOR
Intervention: Periodontal pocket therapy alone (Control)
Number of subjects: 10
Study 22300693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 500 mg twice daily for 4 weeks
Number of subjects: 17
Study 22300693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 17
Study 22300693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 19088307 — intervention group
Group type: COMPARATOR
Intervention: Control formula (n = 25)
Number of subjects: 134
Study 19088307 — intervention group
Group type: EXPERIMENTAL
Intervention: Control formula supplemented with PDX and GOS (4 g/liter) (PG4 group; n = 27)
Number of subjects: 134
Study 19088307 — intervention group
Group type: EXPERIMENTAL
Intervention: Control formula supplemented with PDX, GOS, and lactulose (4 g/liter) (PGL4 group; n = 27)
Number of subjects: 134
Study 19088307 — intervention group
Group type: EXPERIMENTAL
Intervention: Control formula supplemented with PDX, GOS, and lactulose (8 g/liter) (PGL8 group; n = 25)
Number of subjects: 134
Study 19088307 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed group (BF group; n = 30)
Number of subjects: 134
Study 19088307 — intervention group
Group type: COMPARATOR
Intervention: All formula groups (including control, PG4, PGL4, PGL8)
Number of subjects: 134
Study 19088307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial community profiles for BF, PG4, PGL4, and PGL8 groups
Number of subjects: 134
Study 19088307 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study 17169532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-response index (CRI) measured as log transformation of the 63% rewarming time upon cold challenge in RP patients (n=50)
Number of subjects: 146
Study 17169532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-response index (CRI) measured in scleroderma patients (n=46)
Number of subjects: 146
Study 17169532 — intervention group
Group type: COMPARATOR
Intervention: Cold-response index (CRI) in controls (n=53)
Number of subjects: 146
Study 17169532 — intervention group
Group type: EXPERIMENTAL
Intervention: Single low-level systemic hyperthermia treatment in scleroderma patients (n=46)
Number of subjects: 146
Study 17169532 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fingertip temperature in primary and scleroderma-associated RP
Number of subjects: 146
Study 16400513 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 20 units of botulinum toxin into the internal anal sphincter
Number of subjects: 30
Study 16400513 — intervention group
Group type: COMPARATOR
Intervention: Injection of 0.4 ml of saline into the internal anal sphincter
Number of subjects: 30
Study 12105311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 0
Study 12105311 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0
Study 12105311 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 0
Study 12105311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9448174 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without peptic strictures
Number of subjects: 79
Study 9448174 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with peptic strictures
Number of subjects: 79
Study 9448174 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without strictures)
Number of subjects: 79
Study 7639162 — intervention group
Group type: EXPERIMENTAL
Intervention: RV‐>SVC
Number of subjects: 25
Study 7639162 — intervention group
Group type: EXPERIMENTAL
Intervention: RV‐>patch
Number of subjects: 25
Study 7639162 — intervention group
Group type: EXPERIMENTAL
Intervention: RV‐>patch + SVC
Number of subjects: 25
Study 2483580 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 12
Study 2483580 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 12
Study 2483580 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 7027430 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of salsalate
Number of subjects: 42
Study 7027430 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 to 5 g of salsalate daily
Number of subjects: 42
Study 7027430 — intervention group
Group type: COMPARATOR
Intervention: soluble, intravenous or enteric-coated forms of acetylsalicylates
Number of subjects: 42
Study 30621717 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium 110/50 μg once daily (IND/GLY)
Number of subjects: 3362
Study 30621717 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 50/500 twice daily (SFC)
Number of subjects: 3362
Study 27861991 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks (Q2W)
Number of subjects: 101
Study 27861991 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly (QM)
Number of subjects: 101
Study 27861991 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (various doses from 7-420 mg SC)
Number of subjects: 101
Study 25651476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibogaine (20 mg) with paroxetine pretreatment
Number of subjects: 21
Study 25651476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 21
Study 24335445 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9773 low dose (250 U/kg followed by 50 U/kg every 12 hours)
Number of subjects: 300
Study 24335445 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9773 high dose (500 U/kg followed by 100 U/kg every 12 hours)
Number of subjects: 300
Study 24335445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24335445 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9773 low dose
Number of subjects: 300
Study 24335445 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9773 high dose
Number of subjects: 300
Study 24335445 — intervention group
Group type: COMPARATOR
Intervention: AZD9773 and placebo
Number of subjects: 300
Study 22659487 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 μg bid)
Number of subjects: 24
Study 22659487 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg od)
Number of subjects: 24
Study 22659487 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study 20226558 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term diagnosed diabetes
Number of subjects: 4060
Study 20226558 — intervention group
Group type: COMPARATOR
Intervention: Incident diagnosed diabetes
Number of subjects: 4060
Study 18518675 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement technique
Number of subjects: 100
Study 18518675 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted measurements using QMA software
Number of subjects: 100
Study 18518675 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both techniques
Number of subjects: 100
Study 18518675 — intervention group
Group type: COMPARATOR
Intervention: Disagreement cases
Number of subjects: 100
Study 15772571 — intervention group
Group type: EXPERIMENTAL
Intervention: EPT every day (0.625 mg of conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate)
Number of subjects: 99
Study 15772571 — intervention group
Group type: COMPARATOR
Intervention: EPT every other day (0.625 mg of conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate)
Number of subjects: 99
Study 15772571 — intervention group
Group type: EXPERIMENTAL
Intervention: EPT every day
Number of subjects: 99
Study 11955393 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 80 mg epirubicin
Number of subjects: 47
Study 11955393 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg consecutive epirubicin
Number of subjects: 47
Study 11955393 — intervention group
Group type: COMPARATOR
Intervention: 40 mg consecutive mitomycin C
Number of subjects: 47
Study 10544418 — intervention group
Group type: EXPERIMENTAL
Intervention: Roller On (motion of the artificial bed partner)
Number of subjects: 24
Study 10544418 — intervention group
Group type: COMPARATOR
Intervention: Roller Off (stationary roller)
Number of subjects: 24
Study 10544418 — intervention group
Group type: EXPERIMENTAL
Intervention: Roller On
Number of subjects: 24
Study 7588490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfuric acid aerosol preexposure (100 micrograms/m3) followed by ozone exposure (0.08, 0.12, or 0.18 ppm)
Number of subjects: 60
Study 7588490 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride aerosol preexposure (control) followed by ozone exposure (0.08, 0.12, or 0.18 ppm)
Number of subjects: 60
Study 7588490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of normal and asthmatic subjects
Number of subjects: 60
Study 2148148 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 42
Study 2148148 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 42
Study 6750929 — intervention group
Group type: EXPERIMENTAL
Intervention: 99m‐Tc‐MDP or 99m‐Tc‐DTPA administration
Number of subjects: 67
Study 6750929 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha- and betamimetics, cholinesterase inhibitors
Number of subjects: 67
Study 6750929 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study 30732459 — intervention group
Group type: EXPERIMENTAL
Intervention: Program A (two months without acute analgesics or migraine medications)
Number of subjects: 72
Study 30732459 — intervention group
Group type: COMPARATOR
Intervention: Program B (two months with acute medications restricted to two days/week)
Number of subjects: 72
Study 28533058 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 82
Study 28533058 — intervention group
Group type: COMPARATOR
Intervention: No Music Therapy
Number of subjects: 82